title: [An effect of cytoprotective therapy on stress resistance and compensatory abilities of patients with chronic cerebral ischemia].
abstract: OBJECTIVE
  To study an effect of nonspecific cytoprotective therapy on clinical manifestations, disease course and indicators of stress system in patients with different stages of chronic cerebral ischemia (CCI).
  
  
  METHODS
  Authors examined 266 patients with CCI, aged from 35 to 55 years. The patients received basic and nonspecific cytoprotective therapy. The dynamics of subjective and objective symptoms of encephalopathy, clinical outcomes after a year of observation, and the state of stress system were analyzed. An effect of therapy on stress was assessed by the dynamics of blood pressure reactions to stress.
  
  
  CONCLUSIONS
  An open randomized comparative study has shown that the inclusion of the drug with nonspecific cytoprotective actions (cytoflavin) in the therapeutic complex improves the therapeutic effect on the clinical manifestations of CCI. The higher frequency of favorable outcomes over one year of follow-up is associated with the optimization of stress system activity under nonspecific cytoprotective therapy and the increase in stress resistance.
authors.affiliation: Nizhny Novgorod State Medical Academy, Nizhny Novgorod.
authors.forename: E A
authors.initials: EA
authors.lastname: Antipenko
authors.affiliation: National Research University 'Lobachevsky Nizhny Novgorod State University', Nizhny Novgorod.
authors.forename: A V
authors.initials: AV
authors.lastname: Derugina
authors.affiliation: Nizhny Novgorod State Medical Academy, Nizhny Novgorod.
authors.forename: A V
authors.initials: AV
authors.lastname: Gustov
mesh_terms: D000328:Adult; D000975:Antioxidants / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000097:blood / Q000188:drug therapy*; D002908:Chronic Disease; D004338:Drug Combinations; D005260:Female; D005486:Flavin Mononucleotide / Q000627:therapeutic use*; D006801:Humans; D007290:Inosine Diphosphate / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009536:Niacinamide / Q000627:therapeutic use*; D013312:Stress, Physiological / Q000187:drug effects; D013386:Succinates / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D004338:Drug Combinations; D018696:Neuroprotective Agents; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate